Navigation Links
Clinician Reports Fast Healing of Intractable Wounds Using MEDIHONEY(R)
Date:4/29/2009

Jason Hanft of Baptist Health South Florida Reports on 11 Patients at SAWC

PRINCETON, N.J., April 29 /PRNewswire-FirstCall/ -- Derma Sciences (OTC Bulletin Board: DSCI), a provider of advanced wound care products, announced that yesterday at the annual Symposium on the Advances in Wound Care (SAWC) in Dallas, Jason R. Hanft, DPM, Director of Medical Education at Baptist Health South Florida, revealed details of a recently concluded 11-patient venous leg ulcer (VLU) case series involving the use of Derma Sciences' MEDIHONEY(R). Dr. Hanft's presentation was part of the general agenda of the conference, where 24 out of 370 abstracts were selected for oral presentation. In addition, 6 other abstracts dealing with MEDIHONEY were presented at SAWC. SAWC is the largest gathering of multidisciplinary wound-care clinicians in the United States.

The study was a confirmatory case series following a positive large 108-patient randomized controlled study published in 2008 on a similar patient population, all of whom suffered from non-healing VLUs, a particularly painful and difficult-to-heal chronic wound. In the recent case series, 11 patients were enrolled with VLUs that had not healed with other advanced wound care modalities - including the gold standard multi-layered compression, as well as silver antimicrobial dressings, hyperbaric oxygen therapy, and antibiotic therapy - for at least 4 months' duration. The study was designed to measure the percentage of wounds that healed in the standard timeframe of 12 weeks, but all 11 wounds healed within 6 weeks, with over half healing within 4 weeks.

According to Dr Hanft, "As renewed interest in the use of sterile, medical-grade honey to achieve wound closure increases, justified by increased scientific and clinical data, the healing potential of MEDIHONEY may serve as a pivotal clinical decision to accelerate the closure of recalcitrant wounds of the lower extremity."

Derma Sciences said that sales of MEDIHONEY continue to increase steadily, most commonly being used on non-healing, chronic wounds. These difficult-to-heal wounds typically comprise about 50% of the wounds affecting an estimated 6.5 million people in the US annually. With an over-the-counter 510K clearance already in place, Derma is completing the development of dressings for the consumer market that would be effective on a wide variety of common wounds, abrasions, and minor burns. As announced previously, these dressings are expected to be in the US retail distribution channel by 2010.

Additional clinical abstracts on the use of MEDIHONEY presented at the SAWC include:

  • Active Leptospermum Honey - A Debriding Alternative (Mary Brennan, North Shore Long Island Jewish Hospital, NY)
  • Utilizing Leptospermum Honey in the Treatment of Cutaneous Small Vessel Vasculitis (CSVV) (Mary Allison Hendrickson, Baylor Health Care System, TX)
  • Use of Active Leptospermum Honey Dressings in the Home Care Setting (Tim Larson, Cleveland Clinic, OH)
  • Active Leptospermum Honey: Treatment for Various Lower Extremity Dermatologic Issues (Tracey Vlahovic, Temple University, PA)
  • Squamous Cell Carcinoma of the Head and Neck: Using Active Leptospermum Honey for Wound Management and Odor Control (Scott Moore, Edmund Oncology Center, OK)
  • The use of Active Leptospermum Honey in a variety of non-healing wounds in the Long Term Care Setting (Mary Webb, San Mateo Medical Center, CA)

About Derma Sciences

Derma Sciences is a global manufacturer and marketer of advanced wound care products. Its key product, MEDIHONEY(R), is sold throughout the world by Derma Sciences and Comvita New Zealand -- the licensor of the patented honey-based technology -- and is the leading brand of honey-based dressings for the management of wounds and burns. The product has been shown to be effective in a variety of wounds and burns, and was the focus of a positive large-scale randomized controlled trial on leg ulcers. Derma's recently FDA cleared BIOGUARD(TM) Barrier Dressing is the Company's latest new product entrant into the $14 billion global wound care market. The barrier technology was licensed from Quick-Med Technologies, Inc. in Q1 of 2007. Derma also has in development DSC127, a novel angiotensin analog for accelerated wound healing and scar reduction. DSC127 was licensed from the University of Southern California in Q4 of 2007. Patient enrollment for a Phase II study began in Q4 of 2008. Results from this study are expected to be submitted to the FDA in Q2 of 2010.

For more information about Derma Sciences, Inc., visit http://www.dermasciences.com.

    Contact:

    Derma Sciences, Inc.
    Edward J. Quilty
    Chairman and CEO
    equilty@dermasciences.com
    (609) 514-4744

    Allen & Caron Inc
    Rudy Barrio (US Investors)
    r.barrio@allencaron.com
    (212) 691-8087

    Brian Kennedy (Media)
    brian@allencaron.com
    (212) 691-8087


'/>"/>
SOURCE Derma Sciences, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Alegent Health Sees Positive Results From Recent Clinician Usability Study Collaboration With Siemens and Motion Computing
2. Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2009 First Quarter Results
3. Human Genome Sciences Reports Positive Late-Breaker Results at EASL from ACHIEVE Phase 3 Trials of Albuferon(R) in Patients with Chronic Hepatitis C
4. An Independent Study Reports on the Utility of ImmuKnow(R), the Cylex(TM) Immune Cell Function Assay, for Monitoring Heart Transplant Recipients
5. InterMune Reports Presentation of Triple Combination Study of ITMN-191 at European Association for the Study of the Liver (EASL)
6. Addrenex Pharmaceuticals Reports Positive Results in Second Phase 3 Study of ADHD Medication
7. Peregrine Pharmaceuticals Reports Positive Preliminary Data From Phase II Bavituximab Lung Cancer Trial
8. Cardium Reports on Applicability of Corgentin to Stem Cell Therapies: Independent Studies Indicate that Ad5IGF-1 Potentiates Stem Cells to Improve Cardiac Function After Heart Attack
9. Poniard Pharmaceuticals Reports Fourth Quarter and Year End 2008 Financial Results and Provides a Corporate Update
10. DURECT Reports Positive Phase IIb Data from TRANSDU(TM)-Sufentanil Clinical Program
11. ExonHit Reports Proof-of-Concept in Breast Cancer Diagnostic Using its SpliceArray(TM) Platform
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... , Belgium , June 24, ... VNRX), today announced the appointment of Dr. ... Directors as a Non-Executive Director, effective June 23, ... Audit, Compensation and Nominations and Governance Committees.  As ... Futcher will provide independent expertise and strategic counsel ...
(Date:6/23/2016)... 23, 2016 Any dentist who has made an ... current process. Many of them do not even offer this ... and high laboratory costs involved. And those who ARE able ... such a high cost that the majority of today,s patients ... Parsa Zadeh , founder of Dental Evolutions Inc. and ...
(Date:6/23/2016)... , June 23, 2016 Research and ... Devices Medical Market Analysis 2016 - Forecast to 2022" ... The report contains up to date financial data derived ... Assessment of major trends with potential impact on the market ... of market segmentation which comprises of sub markets, regional and ...
Breaking Medicine Technology:
(Date:6/25/2016)... , ... June 25, 2016 , ... On Friday, June ... a Bronze Wellness at Work award to iHire in recognition of their exemplary accomplishments ... of the 7th annual Maryland Workplace Health & Wellness Symposium at the BWI Marriott ...
(Date:6/24/2016)... ... 24, 2016 , ... June 19, 2016 is World Sickle Cell Observance Day. ... the benefits of holistic treatments, Serenity Recovery Center of Marne, Michigan, has ... , Sickle Cell Disease (SCD) is a disorder of the red blood cells, which ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... for accelerated orthodontic treatment. Dr. Cheng has extensive experience with all areas of ... AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is a revolutionary adjunct to ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... at the Clinical Decision Making in Emergency Medicine conference in Ponte Vedra Beach, ... journal articles published in Emergency Medicine Practice and Pediatric Emergency Medicine ...
(Date:6/24/2016)... ... ... National recruitment firm Slone Partners is pleased to announce the ... as Vice President of North American Capital Sales at HTG Molecular . ... team in the commercialization of the HTG EdgeSeq system and associated reagents in North ...
Breaking Medicine News(10 mins):